Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screens

Tet Woo Lee1,2, Francis W Hunter3,4,5, Peter Tsai4,6

  • 1Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand. tw.lee@auckland.ac.nz.

Cancer Gene Therapy
|September 8, 2023
PubMed

Insights

Optimizing in vivo CRISPR screens requires careful consideration of experimental parameters. Early tumor harvesting and smaller guide RNA library sizes improve the reliability of gene function evaluation in cancer models.

Area of Science:

  • Cancer Biology
  • Genomics
  • Immunology

Background:

  • In vivo CRISPR/Cas9 knockout screens enable gene function evaluation within the tumor microenvironment.
  • Understanding key parameters is crucial for the success of these screens.

Purpose of the Study:

  • To investigate critical factors influencing the success of transplantable in vivo CRISPR/Cas9 screens.
  • To optimize experimental design for reliable gene function assessment in cancer models.

Main Methods:

  • Evaluated cell line choice, mouse host, tumor harvesting timepoint, and guide RNA (gRNA) library size.
  • Utilized HCT116 cell line and NSG mice for in vivo transplantation.
  • Analyzed gRNA representation and clonal dynamics at different time points.

Main Results:

  • High gRNA representation (80-95%) was maintained in early-harvested tumors (14 days).
  • Late-harvested tumors (38-43 days) showed decreased gRNA representation and increased variance in read counts.
  • Expansion of random clones and increased 'noise' limited gRNA-based selection detection in later time points.

Conclusions:

  • Early tumor harvesting and optimized gRNA library size are critical for robust in vivo CRISPR screening.
  • Rationally designed screens can improve the power for evaluating gene function in cancer research.